The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma

被引:2
作者
Tascilar, M
Skinner, HG
Rosty, C
Sohn, T
Wilentz, RE
Offerhaus, GJA
Adsay, V
Abrams, RA
Cameron, JL
Kern, SE
Yeo, CJ
Hruban, RH
Goggins, M
机构
[1] Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[6] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
[7] Wayne State Univ, Sch Med, Harper Hosp,Detroit Med Ctr, Karmanos Canc Inst,Dept Pathol, Detroit, MI USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: SMAD4 (also called Dpc4) is a tumor suppressor in the TGF-beta signaling(1) pathway that is genetically inactivated in similar to 55% of all pancreatic adenocarcinomas. We investigated whether prognosis after surgical resection for invasive pancreatic adenocarcinoma is influenced by SMAD4 status. Experimental Design: Using immunohistochemistry, we characterized the SMAD4 protein status of 249 pancreatic adenocarcinomas resected from patients who underwent pancreaticoduodenectomy (Whipple resection) at The Johns Hopkins Hospital, Baltimore, MD, between 1990 and 1997. The SMAD4 gene status of 56 of 249 (22%) pancreatic carcinomas was also determined. A multivariate Cox proportional hazards model assessed the relative risk of mortality associated with SMAD4 status, adjusting for known prognostic variables. Results: Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival (unadjusted median survival was 19.2 months as compared with 14.7 months in patients with pancreatic cancers lacking SMAD4 protein expression; P = 0.03). This SMAD4 survival benefit persisted after adjustment for prognostic factors including tumor size, margins, lymph node status, pathological stage, blood loss, and use of adjuvant chemoradiotherapy. The relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01-1.83; P = 0.04). Conclusion: Patients undergoing Whipple resection for pancreatic adenocarcinoma survive longer if their cancers express SMAD4.
引用
收藏
页码:4115 / 4121
页数:7
相关论文
共 50 条
[21]   SMAD4 deficient pancreatic adenocarcinoma are poor prognosis tumours associated with histopathological aggressive features [J].
Fenouil, T. ;
Caligaris, C. ;
Bertrand, A. ;
Santis, S. ;
Bartholin, L. ;
Hervieu, V. .
VIRCHOWS ARCHIV, 2019, 475 :S21-S21
[22]   New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas [J].
Yao, Hongjuan ;
Luo, Liaoxin ;
Li, Rui ;
Zhao, Yelin ;
Zhang, Li ;
Pesic, Milica ;
Cai, Lin ;
Li, Liang .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (06)
[23]   Implications of SMAD4 Genetic Status in Recurrent Pancreatic Adenocarcinoma [J].
AlMasri, S. S. ;
Zenati, M. ;
Singhi, A. D. ;
Lee, K. K. ;
Bahary, N. ;
Bartlett, D. ;
Zureikat, A. .
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) :S29-S29
[24]   Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only [J].
Niki A. Ottenhof ;
Folkert H. M. Morsink ;
Fiebo ten Kate ;
Cornelis J. F. van Noorden ;
G. Johan A. Offerhaus .
Cellular Oncology, 2012, 35 :119-126
[25]   Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only [J].
Ottenhof, Niki A. ;
Morsink, Folkert H. M. ;
ten Kate, Fiebo ;
van Noorden, Cornelis J. F. ;
Offerhaus, G. Johan A. .
CELLULAR ONCOLOGY, 2012, 35 (02) :119-126
[26]   SMAD4/DPC4 and pancreatic cancer survival - Commentary re: M. Tascilar et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res., 7: 4115-4121, 2001. [J].
Liu, F .
CLINICAL CANCER RESEARCH, 2001, 7 (12) :3853-3856
[27]   A study of Smad4, Smad6 and Smad7 in surgically resected samples of pancreatic ductal adenocarcinoma and their correlation with clinicopathological parameters and patient survival [J].
Singh P. ;
Srinivasan R. ;
Wig J. ;
Radotra B. .
BMC Research Notes, 4 (1)
[28]   SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer [J].
Blackford, Amanda ;
Serrano, Oscar K. ;
Wolfgang, Christopher L. ;
Parmigiani, Giovanni ;
Jones, Sian ;
Zhang, Xiaosong ;
Parsons, D. Williams ;
Lin, Jimmy Cheng-Ho ;
Leary, Rebecca J. ;
Eshleman, James R. ;
Goggins, Michael ;
Jaffee, Elizabeth M. ;
Iacobuzio-Donahue, Christine A. ;
Maitra, Anirban ;
Cameron, John L. ;
Olino, Kelly ;
Schulick, Richard ;
Winter, Jordan ;
Herman, Joseph M. ;
Laheru, Daniel ;
Klein, Alison P. ;
Vogelstein, Bert ;
Kinzler, Kenneth W. ;
Velculescu, Victor E. ;
Hruban, Ralph H. .
CLINICAL CANCER RESEARCH, 2009, 15 (14) :4674-4679
[29]   Loss of Smad4 induces SPP1 secretion and immunosuppressive myeloid cell formation in pancreatic ductal adenocarcinoma [J].
Murimwa, Gilbert Z. ;
Rossi, Francesca ;
Fleming, Henry K. ;
Yazgan, Zeynep ;
Alzhanova, Dina ;
Huang, Huocong ;
Brekken, Rolf A. .
CANCER RESEARCH, 2023, 83 (07)
[30]   SMAD4 and TGFβR2 expression in pancreatic ductal carcinoma [J].
Vaduva, Ion Alexandru ;
Margaritescu, Claudiu ;
Georgescu, Claudia-Valentina ;
Enache, Andreea-Oana ;
Padureanu, Rodica ;
Saftoiu, Adrian ;
Pirici, Daniel .
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2019, 60 (03) :803-809